Kiromic’s focus is creating the next generation of immunotherapy
BSK01™ is Kiromic’s most advanced clinical product and the result of more than 20 years of research in the field performed by Kiromic team.
It is an autologous mature dendritic cell-based therapy that is FDA-cleared for Phase I/II clinical trials for solid and hematologic malignancies
In the clinic, a patient’s immune cells (dendritic cells) are harvested, and trained to attack and defeat cancer cells carrying the K.A.I-BLADE™ identified targets that are specific to the patients cancer type and medical history. Dendritic cells that have been trained against a cocktail of cancer antigens are engineered into a proprietary injectable drug called BSK01™ Thus, BSK01™ is a flexible system that can be used to trigger immune responses to a defined set of tumor antigens that can be modified according to the antigenic phenotype displayed by the patient’s particular tumor.